Heska Corp (HSKA) Earns Buy Rating from Analysts at Aegis

Aegis initiated coverage on shares of Heska Corp (NASDAQ:HSKA) in a report released on Thursday morning. The brokerage issued a buy rating and a $114.50 price objective on the medical research company’s stock.

HSKA has been the topic of a number of other reports. Zacks Investment Research raised Heska Corp from a hold rating to a buy rating and set a $102.00 price objective on the stock in a research report on Thursday, March 2nd. Benchmark Co. lifted their price objective on Heska Corp from $78.00 to $100.00 and gave the company a hold rating in a research report on Monday, February 6th. Finally, B. Riley reaffirmed a neutral rating and set a $83.00 price objective on shares of Heska Corp in a research report on Friday, April 28th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $95.50.

Shares of Heska Corp (NASDAQ:HSKA) opened at 94.53 on Thursday. The stock has a market capitalization of $672.68 million, a P/E ratio of 50.63 and a beta of 0.83. Heska Corp has a 12-month low of $32.26 and a 12-month high of $110.25. The firm’s 50-day moving average is $98.95 and its 200 day moving average is $86.58.

Heska Corp (NASDAQ:HSKA) last announced its earnings results on Tuesday, May 2nd. The medical research company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.37. Heska Corp had a return on equity of 10.46% and a net margin of 7.55%. The business had revenue of $30.38 million for the quarter, compared to analysts’ expectations of $33.31 million. Heska Corp’s revenue was up 11.9% compared to the same quarter last year. On average, equities research analysts forecast that Heska Corp will post $1.98 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Heska Corp (HSKA) Earns Buy Rating from Analysts at Aegis” was first reported by Mideast Time and is the sole property of of Mideast Time. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.mideasttime.com/heska-corp-hska-earns-buy-rating-from-analysts-at-aegis/1754992.html.

In related news, EVP Rod Lippincott sold 11,227 shares of the business’s stock in a transaction that occurred on Wednesday, May 31st. The stock was sold at an average price of $98.00, for a total value of $1,100,246.00. Following the transaction, the executive vice president now directly owns 11,292 shares of the company’s stock, valued at approximately $1,106,616. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Michael J. Mcginley sold 11,189 shares of the business’s stock in a transaction that occurred on Wednesday, May 31st. The stock was sold at an average price of $98.53, for a total value of $1,102,452.17. Following the completion of the transaction, the insider now directly owns 111,877 shares in the company, valued at $11,023,240.81. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,130 shares of company stock worth $4,071,872. Insiders own 15.30% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its position in Heska Corp by 199.4% in the first quarter. Goldman Sachs Group Inc. now owns 28,861 shares of the medical research company’s stock worth $3,030,000 after buying an additional 19,220 shares in the last quarter. Jane Street Group LLC acquired a new position in Heska Corp during the first quarter worth approximately $228,000. AQR Capital Management LLC boosted its position in Heska Corp by 8.5% in the first quarter. AQR Capital Management LLC now owns 41,462 shares of the medical research company’s stock worth $4,353,000 after buying an additional 3,240 shares in the last quarter. Gotham Asset Management LLC acquired a new position in Heska Corp during the first quarter worth approximately $1,492,000. Finally, Highbridge Capital Management LLC acquired a new position in Heska Corp during the first quarter worth approximately $605,000. 77.40% of the stock is currently owned by institutional investors.

Heska Corp Company Profile

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:HSKA”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Heska Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.